TY - JOUR
T1 - Drug-encapsulated carbon (DECON)
T2 - A novel platform for enhanced drug delivery
AU - Yadavalli, Tejabhiram
AU - Ames, Joshua
AU - Agelidis, Alex
AU - Suryawanshi, Rahul
AU - Jaishankar, Dinesh
AU - Hopkins, James
AU - Thakkar, Neel
AU - Koujah, Lulia
AU - Shukla, Deepak
N1 - Funding Information:
This work was supported by grants from the NIH (R01 EY024710, RO1 AI139768, and RO1 EY029426) to D.S. A.A. was supported by an F30EY025981 grant from the National Eye Institute, NIH.
Publisher Copyright:
Copyright © 2019 The Authors.
PY - 2019/8/14
Y1 - 2019/8/14
N2 - Current drug-delivery systems are designed primarily for parenteral applications and are either lipid or polymer drug conjugates. In our quest to inhibit herpes simplex virus infection via the compounds found in commonly used cosmetic products, we found that activated carbon particles inhibit infection and, in addition, substantially improve topical delivery and, hence, the efficacy of a common antiviral drug, acyclovir (ACV). Our in vitro studies demonstrate that highly porous carbon structures trapped virions, blocked infection and substantially improved efficacy when ACV was loaded onto them. Also, using murine models of corneal and genital herpes infections, we show that the topical use of drug-encapsulated carbon (DECON) reduced dosing frequency, shortened treatment duration, and exhibited higher therapeutic efficacy than currently approved topical or systemic antivirals alone. DECON is a nontoxic, cost-effective and nonimmunogenic alternative to current topical drug-delivery systems that is uniquely triggered for drug release by virus trapping.
AB - Current drug-delivery systems are designed primarily for parenteral applications and are either lipid or polymer drug conjugates. In our quest to inhibit herpes simplex virus infection via the compounds found in commonly used cosmetic products, we found that activated carbon particles inhibit infection and, in addition, substantially improve topical delivery and, hence, the efficacy of a common antiviral drug, acyclovir (ACV). Our in vitro studies demonstrate that highly porous carbon structures trapped virions, blocked infection and substantially improved efficacy when ACV was loaded onto them. Also, using murine models of corneal and genital herpes infections, we show that the topical use of drug-encapsulated carbon (DECON) reduced dosing frequency, shortened treatment duration, and exhibited higher therapeutic efficacy than currently approved topical or systemic antivirals alone. DECON is a nontoxic, cost-effective and nonimmunogenic alternative to current topical drug-delivery systems that is uniquely triggered for drug release by virus trapping.
UR - http://www.scopus.com/inward/record.url?scp=85070874571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070874571&partnerID=8YFLogxK
U2 - 10.1126/sciadv.aax0780
DO - 10.1126/sciadv.aax0780
M3 - Article
C2 - 31453334
AN - SCOPUS:85070874571
SN - 2375-2548
VL - 5
JO - Science Advances
JF - Science Advances
IS - 8
M1 - eaax0780
ER -